Pfizer reports Elrexfio progression-free survival estimates
Over 75% of Elrexfio patients were progression-free; estimated progression-free survival was 68% at 18 months.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.